for recreational or "medical" purposes, that presents the potential negative effect on gut motility.
| C A S E S TUDY
A 51-year-old female with prior history of cholecystectomy, hysterectomy, migraine, and bronchial asthma presented with acute worsening of nausea, vomiting, and abdominal pain. She denied using showers to relieve her symptoms. She underwent removal of a residual 1 cm common bile duct stone (which unfortunately did not relieve her symptoms). Upper gastrointestinal endoscopy, ultrasound, CT, and MR of the abdomen were otherwise unremarkable. She was also treated for constipation and abdominal wall tenderness associated with a trigger point. She acknowledged prior use of marijuana. Gastric emptying of a 300 kcal, 30% fat, solid-liquid meal was markedly delayed. On the other hand, gastroduodenal manometry showed essentially normal amplitude antral phasic pressure, reduced antral frequency, no evidence of pylorospasm and well-coordinated small bowel phasic pressure activity ( Figure 1 ).
| OBJEC TIVE S
The current article demonstrates the role of cannabinoids in caus- 
Key Points
• Cannabinoid agents have significant effects on gastric and colonic motility. Patients are increasingly resorting to the use of cannabis. It is important that physicians understand the effects of cannabinoid agents.
• The aim was to increase awareness for gastroenterologists of the effects of cannabinoids on gastrointestinal motility.
Method: This is a narrative, comprehensive review of the literature on cannabinoids and gastrointestinal motor functions in animals and humans.
• Novel therapeutic cannabinoid approaches are being developed that could impact gastrointestinal symptoms.
Meanwhile, it is important to note that cannabinoid agonists (CBR1 target) may delay gastric emptying (especially in females) and inhibit colonic motility.
| CURRENT US E OF C ANNAB INOIDS
There is moderate quality evidence to support the use of cannabinoids (CB) for the treatment of chronic pain and spasticity, and there is low quality evidence suggesting improvements in nausea and vomiting due to chemotherapy, weight gain in HIV infection, sleep disorders, and Tourette syndrome. 9 There is also some analgesic benefit provided by selective CB in patients with chronic neuropathic pain. 10 However, there is increased risk of short-term adverse events, the most frequent being tachycardia, agitation, and nausea. 11 Nevertheless, CB are increasingly used as medicinal or recreational agents, particularly in states having decriminalized medical and recreational cannabis, where unintentional cannabis ingestion by children, 12 in utero effects on fetal neural development associated with cannabis use during pregnancy, 13 and cannabinoid hyperemesis syndrome are increasingly recognized.
14 Synthetic CB products have effects that are somewhat similar to those of natural cannabis, but are more potent and long-lasting than Δ 9 -tetrahydrocannabinol (THC). Some of these compounds are potent and dangerous, having been linked to psychosis, mania, and suicidal ideation. 15 
| B I OSYNTHE S IS OF ENDOC ANNAB INOIDS
Endocannabinoids are biosynthesized "on demand" from membrane phospholipids and they are released immediately after their production. Following receptor activation and induction of a biological response, endocannabinoids are inactivated (Figure 2 ) through reuptake by putative endocannabinoid membrane transporters (EMT), . 1, 5, 16 These catalytic enzymes have also been identified in the digestive tract. 6, 7 Apart from effects on CB receptors, the endocannabinoid, anandamide, may also activate the transient receptor potential (TRP) vanilloid type 1 (TRPV1), which is mainly expressed by primary afferent neurons and the orphan G protein-coupled receptor GPR55. 8 The enzymes involved in biosynthesis and degradation of endocannabinoids in the nervous system are extensively reviewed elsewhere. 17 The main properties of CB receptor agonists and antagonists to which the following discussion refers are listed in Table 1 . 
| C ANNAB INOID RECEP TOR S AND ENDO C ANNAB INOID E XPRE SS I ON IN THE G A S TROINTE S TINAL TR AC T
CB
| BA S IC PHARMACOLOGY DEMONS TR ATING EFFEC TS OF C ANNAB INOID MODUL ATION ON G UT MOTILIT Y
The profound effects of CB on gut motility were demonstrated in vitro in studies involving human and animal tissues.
CB receptors significantly impact intestinal motility in rats, as
shown through systematic studies using pharmacological agonists (WIN-55,212-2 and CP-55,940) and antagonists of the CB 1 (SR141716A) and CB 2 receptors (SR144528). 
4.
A CB1 mega-agonist, AM841, has negligible central effects at doses that dose-dependently reduce transit in rat stomach in vivo, small intestine, cecum, and colorectum. In addition, effects on compliance or tone could be inferred from morphometric analysis of stomach and cecum size by radiographic imaging.
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| PHARMACODYNAMIC EFFEC TS OF C ANNAB INOIDS ON HUMAN G A S TROINTE S TINAL AND COLONIC MOTILIT Y
In human studies, most of the observations on CB effects have emanated from studies of the approved pharmacological agent, dronabinol, a synthetic delta-9-tetrahydrocannabinol (Δ 9 -THC). This is a non-selective CB agonist that is 90%-95% absorbed after a single oral dose, undergoes extensive first pass hepatic metabolism, and has high lipid solubility, so that 10%-20% of the administered oral dose reaches the systemic circulation. Its onset of action occurs at approximately 0.5-1 hour, and its peak effect occurs at 2-4 hours.
Elimination follows a two-compartment model with initial half-life of ~4 hours and terminal half-life of 25-36 hours. It undergoes hepatic metabolism, primarily by microsomal hydroxylation, yielding both active and inactive metabolites, and biliary excretion is the major route of elimination.
Effects on human gastric functions-Dronabinol delays gastric
emptying of solids, 31 and this effect was seen predominantly in females (Figure 3 ). There were no significant effects of dronabinol on postprandial gastric volumes (accommodation), 
| AB NORMAL C ANNAB INOID MECHANIS MS IN G A S TROINTE S TINAL DYS MOTILIT Y
Cannabinoids are recognized as etiologic factors in adult patients presenting with cyclic vomiting syndrome (CVS) and cannabinoid hyperemesis. CVS is quite prevalent (10.8%) among patients presenting to outpatient gastroenterology clinics with intermittent episodes of nausea and vomiting. Identified associations of CVS include younger age, tobacco smoking, psychiatric comorbidity, and symptoms compatible with other FGIDs. 37 Cannabinoid hyperemesis presents either during use or withdrawal from cannabis and is associated with a stereotypical craving for showers to relieve symptoms. 38 In addition to the role of CB in cyclic vomiting syndrome and CB hyperemesis, there are 2 commonly encountered gastrointestinal dysmotilities in human or animal models that have been associated with altered CB expression or mechanisms. Decreased enteric FAAH activity is associated with colonic inertia in STC; conversely, CB 1 expression appears to be non-significantly increased. 32 The orphan G proteincoupled receptor, GPR55, is a novel receptor that is a target of anandamide and cannabidiol and is involved in regulation of rodent intestinal motility. 39 It was shown that there was increased expression of GPR55 in a streptozotocin mouse model of gastroparesis, suggesting that CB mechanisms may result in inhibition of gastric motility. 40 
| A SSO CIATI ON OF G ENE TI C VARIATI ON S IN FA AH AND CB R1 W ITH PHENOT YPE AND COLONI C TR AN S IT
Further evidence supporting a role of CB mechanisms in gut dysmotility is provided by associations between genetic variations in CB pathways or receptors and gastrointestinal phenotypes, including intermediate phenotypes of motility and transit.
1. FAAH genotype is associated with symptom phenotypes and colonic transit in IBS-diarrhea. 41 2. CNR1 rs806378 is associated with IBS-diarrhea, 42 the CC genotype with symptoms, and, paradoxically, the TT genotype with faster colonic transit, given that the TT (not the CC) group had fastest colonic transit at 24 and 48 hours.
3.
There are different allelic frequencies of AAT repeats in the CNR1 gene in healthy controls and IBS patients in Korea. 43 In studies of colonic transit, there was a CNR1 (AAT)n gene by subgroup interaction, but the significant association was in healthy controls, not in IBS. 
| CURRENT THER APEUTIC APPLIC ATIONS OF C ANNAB INOID MEDIC ATION
Dronabinol is the only approved cannabinoid medication. Reviewing the information and published data on the role of cannabinoids, CB 1 receptors and interactions with sensory neurotransmitters (eg, substance P, CGRP, and TRPV1), Sharkey and Wiley proposed that peripherally restricted CB and modulators of endocannabinoid synthesis and/or degradation might be effective for short-term treatment of symptoms in functional bowel disorders. 17 Cannabinoids are F I G U R E 5 Randomized, controlled trial of THC and placebo in 3 forms of chronic pain showing mean VAS pain scores at baseline and during study treatment showing no significant effect of treatment with THC. Reproduced with permission from Ref. [46] commonly used in relief of chemotherapy-induced nausea and vomiting (CINV), although no good quality evidence to recommend the use of cannabinoids for CINV was identified in a systematic analysis of the literature. 45 Given the inhibition of gastric emptying shown with dronabinol, especially among female participants, the use of dronabinol for nausea due to gastroparesis is unlikely to be efficacious.
Recent studies have assessed the potential of CB in pain syndromes. In a study of 65 patients with chronic abdominal pain for at least 3 months after surgery or pain from chronic pancreatitis, THC administered 3 times daily did not reduce pain measures compared to placebo, although it appeared that THC was safe and well-tolerated over ~7 weeks' treatment 46 ( Figure 5 ). Similarly, THC did not reduce postoperative pain compared to placebo. 47 
| P OTENTIAL THER APEUTI C EFFEC TS WITH NOVEL OR E XPERIMENTAL C ANNAB INOID AG ENTS
The best characterized CB receptors, CB 1 With the development of novel, more specific agonists and antagonists, it is also possible that CB agents may be part of the pharmacological armamentarium to relieve symptoms, independent of possible effects on sensations such as nausea, anorexia, or pain.
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